DisclosureWe earn commission on partner links; ranking is set by clinician-vetted methodology — not advertisers.
8 editorial guides to off-label GLP-1 use. NYT April 2026 reporting: 60%+ of long-term users stay on for non-weight-loss benefits. None are FDA-approved indications.
Semaglutide reduces alcohol craving and intake in early trials. Patients on GLP-1s frequently report spontaneous reductions in drinking that match the mechanism.
GLP-1s significantly reduce binge frequency in early studies. Mechanism: reduced reward response to food + slowed gastric emptying.
Semaglutide showed Phase 3 efficacy in resolving steatohepatitis without fibrosis progression. FDA approval expected 2026-2027.
GLP-1s improve PCOS metabolic features and cycle regularity. "Ozempic babies" phenomenon: patients on GLP-1s conceive unexpectedly as fertility improves.
Early evidence suggests GLP-1s reduce opioid craving. Mechanism may involve dopamine pathway modulation. Phase 2 trials underway.
Patients on GLP-1s for weight loss report unexpected long COVID symptom improvement (fatigue, brain fog, post-exertional malaise). Mechanism unclear; trials enrolling.
Mixed evidence. Some users report mood improvement with weight loss; others report new-onset depression or worsening symptoms. FDA evaluating signal in 2025-2026.